Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: A systematic review.

Nafiu Ismail, MPH\textsuperscript{1,2, *}; Kelvin P. Jordan, DPhil\textsuperscript{1}; Sunil V. Rao, MD\textsuperscript{3}; Tim Kinnaird, MD\textsuperscript{4}; Jessica Potts, DPhil\textsuperscript{2}; Umesh T. Kadam, DPhil\textsuperscript{5}; Mamas A. Mamas, DPhil\textsuperscript{1,2}

*Correspondence to: Nafiu Ismail, Research Institute for Primary Care and Health sciences, Keele University, Keele, Staffordshire, ST5 5BG, United Kingdom.

Email: n.ismail@keele.ac.uk

Telephone: 01782734889

\textsuperscript{1}Research Institute for Primary Care & Health Sciences, Keele University, Keele Staffordshire, ST5 5BG, UK.

\textsuperscript{2}Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK.

\textsuperscript{3}The Duke Clinical Research Institute, Duke University Medical Centre, Durham, NC, USA.

\textsuperscript{4}Department of Cardiology, University Hospital of Wales, Cardiff, Wales, United Kingdom.

\textsuperscript{5}Department of Health Sciences, University of Leicester, Leicester, United Kingdom.

Word count: 3745
ABSTRACT

**Objective** – The primary objective was to determine the incidence of bleeding events post-acute coronary syndrome (ACS) following hospital discharge. The secondary objective was to determine the prognostic impact of bleeding on mortality, major adverse cardiovascular events (MACE), myocardial re-infarction and re-hospitalisation in the post discharge setting.

**Design** – A narrative systematic review

**Data source** - Medline, Embase, Amed and Central (Cochrane) were searched up to August 2018.

**Study selection** - For the primary objective, randomised controlled trials (RCT) and observational studies reporting on the incidence of bleeding post-hospital discharge were included. For the secondary objective, RCTs and observational studies that compared patients with bleeding versus those without bleeding post-hospital discharge vis-à-vis mortality, MACE, myocardial re-infarction and re-hospitalisation were included.

**Results** - 53 studies (36 observational studies and 17 RCTs) with a combined cohort of 714,458 participants for the primary objectives and 187,317 for the secondary objectives were included. Follow-up ranged from 1 month to just over 4 years. The incidence of bleeding within 12-months post-hospital discharge ranged from 0.20 to 37.5 percent in observational studies and between 0.96 and 39.4 percent in RCTs. The majority of bleeds occurred in the initial 3 months after hospital discharge with bruising the most commonly reported event. Major bleeding increased the risk of mortality by nearly threefold in 2 studies. One study showed an increased risk of MACE (HR: 3.00 (95% CI 2.75, 3.27; p<0.0001)) with bleeding and another study showed a non-significant association with re-hospitalisation (HR: 1.20 (95% CI 0.95, 1.52; p=0.13)).

**Conclusion** - Bleeding complications following ACS management are common and continue to occur in the longer term after hospital discharge. These bleeding complications may increase the risk of mortality and MACE, but greater evidence is needed to assess their long-term effects.

**Systematic review registration**  PROSPERO CRD 42017062378

**Keywords:** Post discharge; Outpatient; Bleeding; Haemorrhage; Acute coronary syndrome; Mortality; MACE; Re-hospitalisation.
Strengths and limitations of this study

✓ This is the first systematic review that has examined the incidence and prognostic impacts of bleeding complications post-acute coronary syndrome within the outpatient setting.

✓ The review combined evidence from observational studies and RCT’s involving a total of 714,458 participants for the primary objectives and 187,317 for the secondary objectives.

✓ The studies included in the review were heterogeneous in regards to bleeding definition, the ACS presentation, demographic characteristics of the study participants, severity and type of bleeding examined, length of follow-up, discharged anti-platelet and anti-coagulant regimens, therefore we were unable to pool data quantitatively.

✓ The findings in relation to MACE and re-hospitalisation should serve as hypothesis generating due to limited data.
INTRODUCTION

The management of acute coronary syndrome (ACS) depends on the clinical presentation, with an overall aim of reducing myocardial ischaemia and adverse ischemic events. This goal is fundamentally achieved via therapy with a combination of anti-thrombotic and invasive strategies. Paradoxically, these management strategies whilst achieving the desired goal of reducing ischemic events, increases the risk of bleeding complications. In the clinical trial setting, the incidence of major bleeding is reported to be between 1% and 10% depending on the bleeding definition used, with observational studies reporting incidences of between 2.8% and 11%. However, the emphasis in the majority of these studies has been on major in-hospital or 30-day bleeding events (a composite of in-hospital and post discharge events), with little consideration for events in the longer term after hospital discharge. Post hospital discharge, ACS patients may remain on dual antiplatelet therapy for up to a year, and aspirin indefinitely, so their risk of bleeding complications persist in the longer term.

Major bleeding is an independent predictor of adverse outcomes, including mortality, recurrent MI, stroke and stent thrombosis in patients with ACS. The association between major in-hospital bleeding events and adverse outcomes (most notably mortality) appeared to be maintained regardless of the definition of bleeding used. These adverse events do, however, appear to depend on the anatomic site of the bleed, and the site of bleeding may vary between the in-hospital and the post discharge settings. Whilst the nature of in-hospital bleeds and their association with adverse events has been well described, the timing, types and association of bleeding events that occur late after hospital discharge with clinical outcomes such as mortality is unclear.

To date, there has not been a systematic review of the incidence, types and prognostic impact of bleeding events post hospital discharge for ACS. The primary objective of this systematic review was therefore to determine the incidence, timing and types of post-hospital discharge bleeds within the adult post-ACS population. The secondary objective was to determine the association of post-discharge bleeds with mortality, major adverse cardiovascular events (MACE), re-hospitalization and re-infarction in the outpatient setting.
METHODS

Eligibility criteria

There were two linked objectives for the systematic review. For the primary objective, we selected studies that reported on the incidence, timing and types of bleeding post-ACS post-hospital discharge. For the secondary objective, we included studies that compared patients with versus those without bleeding post-ACS post-hospital discharge in relation to mortality, MACE, myocardial re-infarction and re-hospitalisation. We only included randomised controlled trials (RCTs) where bleeding events were reported as secondary or safety outcomes, and observational studies which were published in English. Studies where the intervention was coronary artery bypass graft surgery (CABG) or elective percutaneous coronary intervention (PCI) were excluded. We also excluded studies where the study population comprised patients with stable angina or other coronary artery disease. See Table 1 for detailed inclusion and exclusion criteria for the review. For studies using the same data source, only one was included in the review, based on: 1) quality, and then by 2) sample size, followed by 3) length of follow-up, unless the studies reported on different outcomes.
Table 1: Inclusion and exclusion criteria specific to primary and secondary objectives

| Primary objective | Inclusion Criteria | Exclusion Criteria |
|-------------------|--------------------|--------------------|
|                   | Participants aged 18 years and over | ✅ Cannot be ascertained whether bleed occurred in-hospital or post-discharge |
|                   | Participants discharged with an ACS diagnosis (UA or STEMI or NSTEMI) at index hospitalisation | ✅ In-hospital bleeds only |
|                   | Randomised controlled trial or Observational study | ✅ Incidence and 95% CI or number of bleeding events cannot be extracted or calculated |
|                   | Bleeding occurred after hospital discharge | ✅ Study population combined patients with ACS and other coronary diseases such as stable angina |
|                   | Any type of bleeding examined (such as gastrointestinal bleed) post hospital discharge for ACS. | ✅ Post-discharge bleeding after PCI, without specifying the clinical presentation for the PCI or whether the PCI was elective. |
|                   | Incidence and associated 95% confidence interval can be extracted or calculated | ✅ Only reporting CABG related bleeds |
|                   | | ✅ Conference/study abstracts, editorials and reviews |

| Secondary objective | Inclusion Criteria | Exclusion Criteria |
|---------------------|--------------------|--------------------|
|                    | Participants aged 18 years and over | ✅ Cannot be ascertained whether bleed occurred in-hospital or post-discharge |
|                    | Participants discharged with an ACS diagnosis (UA or STEMI or NSTEMI) at index hospitalisation | ✅ In-hospital bleeds only |
|                    | Randomised controlled trial or Observational study | ✅ Study population combined patients with ACS and other coronary diseases such as stable angina |
|                    | Bleeding occurred after hospital discharge | ✅ Post-discharge bleeding after PCI, without specifying the clinical presentation for the PCI or whether the PCI was elective. |
|                    | Evaluated outcome of or composite of mortality, MI, re-hospitalisation, and MACE in bleed Vs no bleed cohorts | ✅ Only reporting CABG related bleeds |
|                    | | ✅ Conference/study abstracts, editorials and reviews |

*STEMI*: ST-Elevation Myocardial Infarction, *NSTEMI*: Non ST-Elevation Myocardial Infarction, *UA*: Unstable Angina, *ACS*: Acute Coronary Syndrome, *PCI*: Percutaneous Coronary Intervention, *CI*: Confidence Interval, *CABG*: Coronary Artery Bypass Graft, *MI*: Myocardial Infarction.
Search strategy

MEDLINE (HDAS; 1946 – Aug 2018), EMBASE (Ovid SP; 1974 – Aug 2018), AMED (Ovid SP; 1985 – Aug 2018) and CENTRAL (Cochrane central register of controlled trials) were searched up to August 2018 using a search strategy which combined keywords and related database specific subject headings for both primary and secondary objectives (see supplementary Table 1 for the full search strategy used on the Embase database). The Journal of the American College of Cardiology (JACC), the European Heart Journal (EHJ), Heart, and Circulation were electronically searched for relevant articles and grey literature. The bibliographies of included studies and relevant review articles identified from each database were scrutinised for additional relevant articles. Citation tracking of included studies via Web of Science was carried out to retrieve additional relevant articles.

Study selection

The titles of all identified articles were screened and those which were obviously irrelevant were eliminated at this stage. The abstracts of the remaining articles were screened independently by NI and JP. Discordances were resolved by consensus between NI, JP and MAM. The full texts of the remaining articles were then screened by NI, with JP also screening 1 in 10.

Data extraction

We extracted study characteristics including study design, setting, length of follow-up, in-hospital interventions, participant characteristics, discharged therapy and comorbidities. The outcomes of incidence of post-discharge bleeding and associated 95% confidence intervals, time of bleed, location/type of bleed, and the adjusted and unadjusted associations of bleeding with mortality, MACE, re-infarction and re-hospitalisation were extracted from individual studies onto a pre-piloted and formatted spreadsheet. In studies where incidence and associated 95% confidence intervals were not reported but relevant data was available, incidence per 100 persons at risk were calculated (i.e. essentially as a proportion). For studies that combined in-hospital and post discharge bleeds, and episodes of bleeds were stratified by time (for instance at 30 days, 6 months, 12 months), bleeds that occurred within the initial 30 days were considered to be in-hospital bleeds (decided by consensus of NI, KJP, MAM, and UTK) and therefore removed from the numerator and denominator. Authors of original studies were contacted where necessary data was missing or to confirm methodological aspects or other characteristics of the study.
Quality Assessment

Observational studies and post hoc observational analyses of RCTs were appraised by the Newcastle Ottawa Scale (NOS) for assessing risk of bias in non-randomised studies. The NOS quality assessment scale contains eight items partitioned into three categories of selection, comparability and outcome. A maximum of one star is allocated to a high quality study for each item under selection and outcome and a maximum of two stars under comparability, giving an overall maximum of nine stars. We considered studies with an overall number of stars greater than or equal to six stars as high quality studies. Randomised controlled trials were appraised by the Scottish Intercollegiate Guideline Network (SIGN) quality assessment tool. Each study was categorised as high quality, acceptable quality or low quality based on the standard criteria for this tool. Quality assessment was based on the primary objective of each study as incidence of bleeding was typically reported as safety or secondary outcome measure.

Data Synthesis

A narrative synthesis approach was applied due to heterogeneity in relation to length of follow-up, ACS presentation, definition of bleeding used, type of bleeding examined, severity of bleeding examined, geographical location and discharge therapy across studies. For the primary objective, the narrative synthesis was carried out in stages. Initially, the incidence of bleeding overall was summarised separately for observational studies and RCTs. The incidence of bleeding was then stratified by ACS presentation (ST-Elevation Myocardial Infarction (STEMI), Non ST-Elevation Myocardial Infarction/Unstable Angina (NSTEMI/UA)) and discharge antithrombotic drug combinations and duration (single antiplatelet (SAPT), dual antiplatelet (DAPT) and receipt of oral anticoagulant) in studies that reported these. To assess the incidence of bleeding by time from hospital discharge, the incidence of bleeding was stratified by follow-up time within studies which looked at multiple time periods. Where studies allowed, the incidence of bleeding stratified by major, minor and nuisance bleeds (see supplementary Table 2 for definitions), and the incidence of different types of bleeding events were examined.

We assessed the strength of evidence (SOE) for each secondary outcome following the Agency for Healthcare Research and Quality guideline. For each secondary outcome, assessment was carried out by examining risk of bias, consistency, directness and precision
across studies that reported on this outcome, and a grade allocated as high, moderate, low or insufficient based on these assessments.

**Patient and Public Involvement**

Patients and members of the public did not have any role in the design, conduct, data synthesis or reporting of the study.

**RESULTS**

The search of Medline, Embase, Amed and Central (Cochrane) identified 37 studies.\(^1\)\(^-\)\(^7\) 4 studies were further identified from electronic search of the Journal of American College of Cardiology database,\(^3\)\(^-\)\(^9\) 2 from Web of Science citation index,\(^60\)\(^,\)\(^61\) 9 from bibliographic screening of included studies,\(^4\)\(^,\)\(^62\)\(^-\)\(^69\) and finally, 1 from recommendation by an expert within the field.\(^70\) Overall, 53 studies (36 observational studies and 17 RCTs) were included in the review with a combined cohort of 714,458 participants for the primary objectives and 187,317 for the secondary objectives (see Figure 1). Of the 53 studies, 45 only reported on the primary outcomes, 3 only reported on the secondary outcomes and 5 reported on both primary and secondary outcomes.

**Characteristics of included studies**

The characteristics of included studies (for the primary objective) are summarised in Table 2 for observational studies and Table 3 for RCTs. Overall, 50 studies reported on the primary outcome, of which 68% (n = 34) were cohort studies and 32% (n = 16) were RCTs. The characteristics of included studies for the secondary objective are summarised in Table 4. Overall, 8 studies reported on the secondary outcomes, of which 7 were cohort studies and one was an RCT.

Length of follow up varied from 30 days\(^29\) to just over 4 years\(^69\) post-hospital discharge. The number of participants ranged from 193 to 187,386. The definition for bleeding used by each study in the review are provided in supplementary Table 2. Some studies (n = 23) did not report bleeding events based on recognised definitions (such as BARC). Of the included studies, 27 had specified the in-hospital ACS management strategy. In 26 of these studies, PCI was the baseline management strategy, and in one study the management strategy was a combination of PCI, angiography and medical therapy.

**Risk of bias assessment**
Summaries of risk of bias of individual studies are provided in Tables 2, 3 and 4. 69% (n = 25) of the observational studies were at high risk of bias due to lack of reporting on presence/absence of outcome at start of study, attrition rate, and comparability of cohorts based on analysis (whether study adjusted for confounders or not). 31% (n = 11) were at low risk of bias. 2 RCTs were high risk, 4 were at an acceptable risk of bias and 2 were low risk. The main reasons for low quality in RCTs were inadequate reporting on randomisation, concealment, blinding, adequacy and reliability of outcome measurements. For studies which were post hoc observational analysis of RCTs, five were high risk and four were at low risk of bias.
Table 2: Summary of observational studies included in the review by length of follow-up, bleeding definition used and in-hospital management strategy

| Primary Author | Location | Setting | Study Design | Length of Follow-up | Bleeding Criteria | In-hospital management strategy | N | Participants with Bleed (n) | Crude Incidence of Bleeding per 100 persons and 95% CI | Quality Score |
|----------------|----------|---------|--------------|---------------------|-------------------|-------------------------------|----|--------------------------|---------------------------------|-------------|
| Cuisset et al 2009 | France | In-patient | Prospective cohort | 1 month | TIMI major/minor | PCI | 597 | 16 | 2.68 (1.66, 4.31) * | 2 |
| Braun et al 2014 | Sweden | Registry | Retrospective cohort | 3 months | BARC 2-5 | PCI | 263 | 26 | 9.89 (6.84, 14.1) * | 5 |
| Amin et al 2016 | US | Registry | Retrospective cohort | 6 months | BARC 1-5 | PCI | 9290 | 2246 | 24.2 (23.3, 25.1) * | 5 |
| Amin et al 2013 | US | Registry | Retrospective cohort | 12 months | BARC 1 | PCI | 3560 | 1335 | 37.5 (35.9, 39.1) * | 4 |
| Latteca et al 2016 | France | In-patient | Prospective cohort | 12 months | BARC 1-3 | PCI | 369 | 132 | 35.8 (31.1, 40.8) * | 5 |
| Bacquelin et al 2015 | France | Registry | Prospective cohort | 12 months | BARC 2-5 | PCI | 1006 | 79 | 7.85 (6.35, 9.68) * | 5 |
| Palmerini et al 2014 | Multi-centre | Unclear | Prospective cohort | 12 months | GUSTO (any) | PCI | 1053 | 41 | 3.91 (2.89, 5.26) * | 5 |
| Kassanian et al 2015 | Iran | Registry | Prospective cohort | 12 months | TIMI major/minor | PCI | 1640 | 23 | 7.63 (6.80, 8.54) * | 5 |
| Yetgin et al 2018 | Netherland | Registry | Cohort | 12 months | TIMI major | PCI | 2443 | 23 | 0.94 (0.63, 1.41) * | 5 |
| Fosbol et al 2012 | US | Registry | Prospective cohort | 12 months | Bleed leading to hospitalisation | NR | 7619 | 928 | 12.2 (11.5, 12.9) * | 6 |
| Tsai et al 2010 | Taiwan | Registry | Retrospective cohort | 12 months | Gastrointestinal bleed | NR | 3580 | 273 | 7.63 (6.80, 8.54) * | 5 |
| Garay et al 2016 | Spain | Registry | Retrospective cohort | 12 months | Bleed leading to hospitalization, transfusion, or suspension of antithrombotics | NR | 1375 | 69 | 5.02 (3.98, 6.30) * | 3 |
| Garay et al 2018 | Multi-centre | Registry | Cohort | 12 months | Intracranial bleeding or bleed leading to hospitalisation or transfusion | PCI | 15401 | 489 | 3.18 (2.91, 3.46) * | 5 |
| Effron et al 2018 | US | Registry | Retrospective cohort | 12 months | Bleed leading to hospitalisation or transfusion | PCI | 15788 | 492 | 3.12 (2.86, 3.40) * | 4 |

11
| Study                | Country  | Registry | Cohort Type | Follow-up | Event Description                        | PCI, Angiography | Medically | Hazard Ratio (95% CI) | Reference |
|---------------------|----------|----------|-------------|-----------|------------------------------------------|-----------------|-----------|----------------------|-----------|
| Brinkert et al 2017 | Canada   | Registry | Cohort      | 12 months | Hospitalization with major bleeding       | PCI             | 22312     | 2.72 (2.51, 2.94) *   | 5         |
| Ko et al 2010       | Canada   | Registry | Cohort      | 12 months | Bleed leading to hospitalisation          | PCI             | 8,672     | 2.65 (2.33, 3.01) *   | 6         |
| Boggon et al 2011   | UK       | Registry | Retrospective cohort | 12 months | Any bleeding in patient GPRD or HES record | NR              | 7543      | 11.4 (10.4, 12.6) †   | 5         |
| Carrero et al 2016  | Sweden   | Registry | Prospective cohort | 12 months | Major bleed                               | NR              | 36001     | 0.92 (0.83, 1.03) *   | 7         |
| Graipe et al 2015   | Sweden   | Registry | Prospective cohort | 12 months | Intracranial bleed                        | NR              | 187,386   | 0.32 (0.30, 0.34)     | 6         |
| Wang et al 2015     | US       | Registry | Cohort      | 12 months | Haemorrhagic stroke                       | NR              | 169,863   | 0.20 (0.18, 0.22)     | 5         |
| Barra et al 2013    | Portugal | Inpatient | Prospective cohort | 13.4 months (Mean) | TIMI/GUSTO major criteria | NR     | 852     | 7.04 (5.51, 8.96) *   | 3         |
| Sra et al 2016      | Canada   | Inpatient | Prospective cohort | 15 months | BARC 1-5                                  | PCI             | 2034      | 21.6 (19.9, 23.5) *   | 5         |
| Caneiro et al 2018  | Spain    | Registry | Cohort      | 455 days (Median) | BARC 2 - 3                                | PCI             | 4229      | 11.8 (10.9, 12.8) *   | 6         |
| Sorensen et al 2009 | Denmark  | Registry | Prospective cohort | 476.5 days (Mean) | Fatal and non-fatal bleed           | PCI             | 40812     | 4.82 (4.62, 5.03) *   | 5         |
| Raposeiras et al 2018 | Multi-centre | Registry | Cohort      | 17.2 months (Mean) | BARC 3 or 5                             | PCI             | 4310      | 1.53 (1.21, 1.94) *   | 6         |
| Cuschieri et al 2014 | US       | Registry | Retrospective cohort | 1.7 years (Mean) | Gastrointestinal bleed                   | NR              | 3218      | 3.33 (2.76, 4.00) *   | 4         |
| Wong et al 2006     | UK       | Inpatient | Retrospective cohort | 21 months | CURE major/life threatening               | NR              | 224       | 6.70 (4.10, 10.8) *   | 4         |
| Buresly et al 2005  | Canada   | Registry | Cohort      | 654 days (Mean) | Bleed leading to hospitalisation          | NR              | 21443     | 6.66 (6.33, 7.00) *   | 3         |
| Voss et al 2016     | New Zealand | Registry | Cohort      | 1.94 years (Mean) | Other                                    | NR              | 3666      | 5.88 (5.15, 6.71) *   | 4         |
| Brener et al 2016   | US and Germany | Registry | Prospective cohort | 24 months | TIMI, GUSTO and ACUITY Major bleed         | PCI             | 8582      | 5.17 (4.71, 5.66) *   | 5         |
| Study            | Country | Registry | Cohort          | Time     | Event Description               | Event Rate | Person Years | CI        | p-Value |
|------------------|---------|----------|-----------------|----------|---------------------------------|------------|--------------|-----------|---------|
| Erta et al 2018  | Turkey  | Registry | Cohort          | 24 months| Physician-confirmed bleeding event | NR         | 1010         | 21        | 2.08 (1.36, 3.16) * | 4 |
| Blin et al 2017  | France  | Registry | Cohort          | 3 years  | Hospitalization with bleeding    | NR         | 1585         | 49        | 3.09 (2.35, 4.06) * | 5 |
| Chamberlain et al 2016 | US | Registry | Cohort          | 4.3 years| Other                           | NR         | 1159         | 312       | 26.9 (24.5, 29.6) * | 6 |
| Kazi et al 2015  | US      | Registry | Retrospective   | 4.42 years (Mean) | Major spontaneous bleeding | PCI        | 22527        | 368       | 1.63 (1.48, 1.81) * | 5 |

*Incidence and associated 95% CI calculated from data within study, †Incidence and associated 95% CI reported within study per 100 persons years, CI: Confidence Interval, NR; not reported, BARC; bleeding academic research consortium, GUSTO; global use of strategies to open occluded arteries, TIMI; thrombolysis in myocardial infarction, ACUITY; acute catheterisation and urgent intervention triage strategy, CURE; clopidogrel in unstable angina to prevent recurrent events, GPRD; general practice research database, HES; hospital episodes statistics, AMI; acute myocardial infarction, SD; standard deviation, Q1; lower quartile, Q3; upper quartile.
Table 3: Summary of randomised controlled trials included in the review by length of follow-up, bleeding definition used and in-hospital management strategy

| Primary Author | Location | Trial | Study Design | Length of Follow-up | Bleeding Criteria | In-hospital management strategy | N | Participants with Bleed | Crude Incidence of Bleeding per 100 persons and 95% CI | Quality Score |
|----------------|----------|-------|--------------|---------------------|-------------------|---------------------------------|----|------------------------|---------------------------------------------------|--------------|
| Yusuf et al 2006 | Multi-centre | OASIS - 5 | Randomised controlled trial | 6 months | OASIS-5 major | NR | 20078 | 357 | 1.84 (1.66, 2.03) * | High |
| Jolly et al 2009 | Multi-centre | CURE | Post hoc analysis of RCT | 8 months | CURE major | PCI | 2658 | 28 | 1.07 (0.74, 1.54) * | 6† |
| Khan et al 2015 | Multi-centre | APPRAISE-2 | Post hoc analysis of RCT | 240 days (Median) | Any bleeding event | NR | 7392 | 506 | 7.32 (6.73, 7.96) * | 7† |
| Carraba et al 2016 | Italy | BLESS | Randomised controlled trial | 12 months | BARC 1-3 | PCI | 193 | 76 | 39.4 (32.8, 46.4) * | Acceptable |
| Cuisset et al 2017 | France | TOPIC | Randomised controlled trial | 12 months | BARC ≥ 2 | PCI | 634 | 106 | 16.7 (14.0, 19.8) * | Low |
| Han et al 2015 | China | BRIGHT | Randomised controlled trial | 12 months | BARC 1-5 | PCI | 2194 | 47 | 2.33 (1.76, 3.08) * | Acceptable |
| Savonitto et al 2012 | Italy | Italian Elderly ACS | Randomised controlled trial | 12 months | BARC 2, 3a & 3b | NR | 313 | 3 | 0.96 (0.33, 2.78) * | Acceptable |
| Mrdovic et al 2013 | Serbia | RISK-PCI | Post hoc analysis of RCT | 12 months | TIMI major/minor | PCI | 2045 | 25 | 1.29 (0.87, 1.89) * | 5† |
| Atar et al 2006 | Multi-centre | OPUS-TIMI 16 | Post hoc analysis of RCT | 12 months | Gastrointestinal bleed | NR | 10288 | 104 | 1.02 (0.84, 1.24) * | 5† |
| Kohli et al 2014 | Multi-centre | TRITON-TIMI 38 | Post hoc analysis of RCT | 15 months | TIMI major/minor | PCI | 12674 | 407 | 3.23 (2.94, 3.56) * | 7† |
| Mahaffey et al 2013 | Multi-centre | TRACER | Post hoc analysis of RCT | 502 days (Median) | TIMI major/minor | NR | 11368 | 236 | 2.12 (1.87, 2.41) * | 6† |
| Yeh et al 2015 | US | DAPT | Randomised controlled trial | 18 months | BARC 2-5 | PCI | 3576 | 111 | 3.10 (2.58, 3.72) * | Acceptable |
| Costa et al 2015 | Italy | PRODIGY | Post hoc analysis of RCT | 24 months | BARC 2-5 | PCI | 1465 | 82 | 5.60 (4.53, 6.89) * | 5† |
|-----------------|-------|---------|--------------------------|-----------|---------|-----|------|----|-------------------|----|
| Bonaca et al 2015 | Multi-centre | PEGASUS-TIMI 54 | Randomised controlled trial | 33 months | TIMI major | NR | 21162 | 435 | 2.08 (1.89, 2.28) * | High |
| Nikolsky et al 2015 | Multi-centre | HORIZON-AMI | Post hoc analysis of RCT | 3 years | HORIZON major | PCI | 3602 | 63 | 2.15 (1.68, 2.74) * | 5† |
| Bergen et al 1994 | Netherland | ASPECT | Randomised controlled trial | 37 months | Major bleed | NR | 3404 | 99 | 2.91 (2.39, 3.53) * | Low |

*Incidence and associated 95% CI calculated from data within study, † Quality assessed by Newcastle Ottawa Scale, CI: Confidence Interval, BARC: bleeding academic research consortium, GUSTO: global use of strategies to open occluded arteries, TIMI: thrombolysis in myocardial infarction, CURE: clopidogrel in unstable angina to prevent recurrent events, HORIZON: harmonizing outcomes with revascularisation and stents, RCT: randomised controlled trial, GI: gastrointestinal, Q1: lower quartile, Q3: upper quartile OASIS-5: the fifth organization to assess strategies in acute ischemic syndromes, SIGN: Scottish intercollegiate guideline network, APPRAISE-2: Apixaban for prevention of acute ischemic events, BLESS: Bleeding events and maintenance dose of prasugrel, TOPIC: Timing of platelet inhibition after acute coronary syndrome, BRIGHT: Bivalirudin in acute myocardial infarction vs heparin and glycoprotein inhibitor plus heparin, RISK-PCI: Risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention, TRACER: Thrombin receptor antagonist for clinical event reduction in acute coronary syndrome, OPUS-TIMI 16: Orbofiban in patients with unstable coronary syndrome-thrombolysis in myocardial infarction 16, TRITON-TIMI 38: Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38, DAPT: Dual antiplatelet therapy study, PRODIGY: Prolonging dual antiplatelet treatment after grading stent induced intimal hyperplasia, PEGASUS-TIMI 54: Prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin thrombolysis in myocardial infarction 54, HORIZON-AMI: Harmonizing outcomes with revascularisation and stents in acute myocardial infarction, ASPECT: Anticoagulants in the secondary prevention of events in coronary thrombosis.
Incidence of bleeding

In a cohort of 611,412 participants, 14,217 (2.3%) episodes of bleeds were reported in thirty-four observational studies and 2,685 (2.6%) episodes in a cohort of 103,046 participants in sixteen RCTs (714,458 participants overall). A summary of the incidence from each study is presented by length of follow-up, bleeding definition used and in-hospital management strategy in Table 2 for observational studies and Table 3 for RCTs. The overall incidence of bleeding within 12 months post hospital discharge varied from 0.244 to 37.520 percent in observational studies, and between 0.9642 to 39.453 percent in RCTs.

The incidence of bleeding stratified by ACS presentation (STEMI, NSTEMI/UA) and discharge antithrombotic drug combinations and duration (SAPT, DAPT and receipt of oral anticoagulant) are summarised by length of follow-up and the bleeding definition used in supplementary Tables 3, 4, and 5. Among those discharged on DAPT with aspirin and a thienopyridine, the incidence of bleeding within the first 12 months based on BARC criteria ranged from 3.91 to 38.8 (see supplementary Table 4) in observational studies, and between 0.96 to 47.4 percent in RCTs (see supplementary Table 5).

Eight observational studies23,36,45,47,51,54,59,70 and two RCTs56,58 comprising 53,318 participants reported bleeding episodes at different time points during follow-up. In these studies, around one-half of bleeds that occurred in the first year post hospital discharge for ACS happened in the initial 1 – 3 months (Figure 2).

The incidence of major bleeding events in observational studies (based on BARC 3 – 5) within the first 12 months of hospital discharge was around 1.29 – 3.25 percent. The incidence of minor bleeding events (based on BARC 2) and nuisance bleeds (based on BARC 1) within the same period were around 6.56 – 10.6, and 21.9 – 37.5 percent respectively (see supplementary Table 6 and Figure S1). Generally, bruising (defined as skin haematoma, ecchymoses, petechiae) were the most commonly reported types of bleeding events post hospital discharge (range: 1.49 to 22.5 percent within 12 months) followed by gastrointestinal bleeds (range: 0.25 to 7.63 percent within 12 months; see supplementary Table 7 and Figure S2).

Bleeding and risk of mortality

There was consistent reporting of an association between post discharge bleeding and all-cause mortality in five observational studies39,47,48,57,64 and one RCT53 (Table 4). Major bleeding was associated with nearly threefold increased risk of mortality in the first 12 months of hospital discharge in two studies (Table 4).47,64 Nuisance bleeding events defined as BARC
1 were not associated with mortality, but there was an increased risk of mortality with BARC 2 and 3 bleeds in one RCT,\textsuperscript{53} which increased with bleeding severity (Table 4). The SOE for the outcome of mortality was rated low (supplementary Table 8).

**Bleeding and risk of MACE, re-hospitalisation and re-infarction.**

The adjusted risk (HR) of MACE with bleeding (defined as bleeds leading to hospitalisation or death) was 3.00 (95% CI 2.75, 3.27 in 1 study (Table 4)).\textsuperscript{40} There was a statistically non-significant association between post discharge bleed (defined as BARC 1 bleeds) and risk of re-hospitalisation (adj HR, 1.20 (95% CI 0.95, 1.52 in another study (Table 4)).\textsuperscript{20} There were no studies examining the association between post discharge bleeding and subsequent risk of re-infarction. The SOE for the outcomes of MACE and re-hospitalisation were rated insufficient (supplementary Table 8).
| Primary Author       | Location | Setting | Length of follow-up | Bleeding Criteria | Adjusted/Unadjusted Outcomes | Quality Score |
|----------------------|----------|---------|---------------------|-------------------|-------------------------------|---------------|
|                      |          |         |                     |                   | Mortality | MACE | Re-hospitalisation |                |
| Lamberts et al 2013  | Denmark  | Registry| 12 months           | Fatal and non-fatal bleed | Adj HR 2.79 (95% CI: 2.39, 3.26) | NR | NR | 7 |
| Brinkert et al 2017  | Canada   | Registry| 12 months           | Hospitalisation with major bleeding | Adj OR 2.97 (95% CI: 1.71, 5.15) | NR | NR | 5 |
| Caneiro et al 2018   | Spain    | Registry| 455 days (Median)   | BARC 2 - 3        | Adj HR 5.1 (95% CI, 3.6, 7.7) | NR | NR | 6 |
| Brener et al 2016    | US and Germany | Registry| 24 months           | TIMI, GUSTO and ACUITY Major bleed | Bleeds between 30-365 days; Unadj HR 4.61 (95% CI 1.70, 12.49); Bleeds >365 days; Unadj HR 2.63 (95% CI 0.86, 8.04) | NR | NR | 5 |
| Olsen et al 2015     | Denmark  | Registry| 3.5 years           | Bleed leading to death or hospitalisation | Adj HR 1.51 (95% CI: 1.28, 1.79) | NR | NR | 6 |
| Valgimigli et al 2017| Multi-centre | RCT    | Unclear             | BARC 1 - 3        | BARC 1: Adj HR 0.89 (95% CI: 0.61, 1.31) | NR | NR | 4† |
| Valgimigli et al 2017| Multi-centre | RCT    | Unclear             | BARC 1 - 3        | BARC 2: Adj HR 1.70 (95% CI: 1.23, 2.36) | NR | NR | 4† |
| Valgimigli et al 2017| Multi-centre | RCT    | Unclear             | BARC 1 - 3        | BARC 3a: Adj HR 2.77 (95% CI: 1.86, 4.12) | NR | NR | 4† |
| Valgimigli et al 2017| Multi-centre | RCT    | Unclear             | BARC 1 - 3        | BARC 3b: Adj HR 4.51 (95% CI: 2.86, 7.10) | NR | NR | 4† |
| Valgimigli et al 2017| Multi-centre | RCT    | Unclear             | BARC 1 - 3        | BARC 3c: Adj HR 28.2 (95% CI: 17.5, 45.7) | NR | NR | 4† |

| Sorensen et al 2009  | Denmark  | Registry| 476.5 days (Mean)  | Fatal and non-fatal bleed | NR | Adj HR 3.00 (95% CI: 2.75, 3.27) | NR | 5 |
| Amin et al 2013      | US       | Registry| 12 months          | BARC 1               | NR | Adj HR 1.20 (95% CI: 0.95, 1.52) | NR | 4 |

Adj: adjusted, unadj: unadjusted, HR; hazard ratio, OR; odd ratio, NR: not reported, CI; confidence interval, MACE; Major Adverse Cardiovascular Event, BARC; bleeding academic research consortium, GUSTO; global use of strategies to open occluded arteries, TIMI; thrombolysis in myocardial infarction, ACUITY; acute catheterisation and urgent intervention triage strategy, †: quality assessed by Newcastle Ottawa Scale.
DISCUSSION

Our systematic review is the first to study the incidence, timing, and types of post-discharge bleeding complications, and their association with mortality, MACE, re-infarction and re-hospitalisation. 53 studies were included, comprising 36 observational studies and 17 RCTs with a combined cohort of 714,458 participants for the primary objectives and 187,317 for the secondary objectives. We report that bleeding complications post ACS are common following hospital discharge, and vary by length of follow-up, severity, type and the definition of bleeding used. We report that the incidence of bleeding was highest in the initial three months after hospital discharge for ACS, with bleeding events continuing to occur even after 1 year post discharge. The majority of post discharge bleeding events were nuisance bleeds such as ecchymosis and petechiae, with major bleeding events such as intracranial haemorrhage less common. Whilst there was substantial heterogeneity between studies, we report that up to one third of patients discharged on DAPT will experience bleeding complications, and around 1.3 – 3.3 percent of patients will experience a major bleed in the first 12 months after hospital discharge.

Our review shows that major bleeding may increase the risk of mortality by nearly threefold in the first 12 months after hospital discharge, but the strength of the evidence was weak. We identified very limited data on whether post-discharge bleeding was associated with MACE and re-hospitalisation. Although there was an indication of an association with MACE in one study and re-hospitalisation in another, the latter association did not reach statistical significance.

Clinical Implications

Although current guidelines have recommended dual therapy with aspirin and a thienopyridine for up to 12 months and triple therapy in the presence of comorbid conditions such as atrial fibrillation for shorter periods, it was evident from our study that these maintenance therapies are accompanied by bleeding complications which predominantly occur post hospital discharge. Consideration must therefore be given to ways of minimising these bleeding complications, such as by encouraging clinicians to use risk scoring algorithms such as DAPT, precise-DAPT, BleeMACS score (for ACS patients treated with PCI) or TRILOGY-ACS bleeding risk model (for NSTEMI/UA patients managed medically) to identify patients at higher risk of these bleeding complications, such that maintenance oral antithrombotics or newer oral anticoagulants that have more favourable safety profile than warfarin can be tailored to fit each patient’s risk profile. However, it must be borne in mind
that many of these risk algorithms were developed in the clinical trial setting, and have not yet been validated in unselected cohorts. Aspirin regardless of dose increases the risk of gastrointestinal bleeds.\textsuperscript{79,80} In high risk patients such as those with previous history of these types of bleeds, concomitant use of a proton pump inhibitor as advocated by the ESC guidelines will reduce the future risk of these bleeds.\textsuperscript{81}

**Research implications**

The majority of studies in this review were not primarily designed to investigate the incidence of bleeding complications. This meant that incidences could only be reported here as per 100 persons, i.e. essentially as a proportion, rather than per 100 persons years at risk. This underscores the need to examine the incidence of these bleeding events using high quality observational studies that are more reflective of the real-world populations encountered in clinical practice. The incidence of post-discharge bleeding complications may vary by type of bleed, patient demographics and discharge pharmacotherapy. Future studies should explore factors associated with post-discharge bleeding complications so that risk stratification tools that are more representative of the unselected cohorts encountered in clinical practice (often ignored in RCTs) can be developed to identify individuals at high risk of bleeding post hospital discharge, as most contemporary bleeding risk scores predict in-hospital bleeding events.\textsuperscript{82–84}

We also report that bleeding complications post hospital discharge may be associated with subsequent risk of mortality, although evidence from the literature was limited. The risks of MACE and re-hospitalisation were only reported in two studies, and none of the studies in the review reported on re-infarction. Future research is required to quantify these associations, with particular emphasis on whether nuisance and minor bleeding events that are much more common post hospital discharge also have a prognostic impact. Finally, future research examining these associations should stratify by the timing of bleeding events in order to determine whether the prognostic impacts of these bleeding complications are more pronounced in the early phases of hospital discharge or are equally important in the longer term after hospital discharge.

**Limitations of the review**

This study has several potential limitations. First, the studies included in the review were too heterogeneous in regards to bleeding definition, ACS presentation, demographic characteristics of the study participants, severity and type of bleeding examined, length of follow-up, discharge anti-platelet and anti-coagulant regimens to pool data to obtain an overall incidence and mortality figures. Second, the duration and dosage of discharge antithrombotic
therapy as well as ACS management strategies were not specified in the majority of studies (due to selective reporting), as such we were unable to adequately assess the impact of these factors on the incidence of bleeding. In the majority of studies, episodes of bleeds were extracted to calculate incidence figures. In most of these studies, there was lack of clarity on whether patients were included in the numerator more than once if they had multiple episodes of bleeds. However, since bleeding complications are rare events\textsuperscript{5,7,85} and having more than one episode of bleeding is even rarer, it is unlikely that this would have affected the overall incidence. Similarly, for some studies where episodes of bleeds were reported at different time intervals and the number of people at risk within each time interval were not reported, incidence figures were estimated based on the assumption that there was no attrition, hence these figures may have been underestimated.

**Conclusions**

In this systematic review of 53 studies, bleeding complications post hospital discharge for ACS were found to be common, with bruising the most common. These bleeding complications vary by severity, anatomic source and type of discharge antithrombotic therapy, and whilst most common immediately post-discharge, these bleeds continue to occur in the longer term. There are limited data around the longer term outcomes of patients that sustain bleeding events post hospital discharge for ACS. Further work is required to define the nature, frequency and prognostic impact of such bleeding events, using formal bleeding definitions. Real world risk stratification tools will need to be developed that specifically predict the risk of bleeding complications post discharge to identify high-risk individuals for a more patient-centred approach in managing optimal pharmacotherapy and care.
Declaration of Interests
No, there are no competing interests for any author.

Author Contributions
NI designed the study under the supervision of KJP, MAM, UTK. NI and JP conducted the study and analysed the data. NI wrote the first draft and KJP, MAM, UTK, TK and SVR made critical revision of the manuscript. All authors have approved the final manuscript and KJP, MAM and UTK are the guarantors.

Funding
Funded by North Staffordshire Medical Institute 50th Anniversary Award. The funding body did not have any role in the design, conduct, data synthesis or reporting of the study.

Acknowledgement
The authors thank Joanne L. Jordan, Nadia Corp and Opeyemi Babatunde of the Research Institute for Primary Care and Health Sciences for their support in drafting and conducting the review.

Ethical approval: Not required

Data sharing
The dataset, supplementary appendix and review protocol are available from the corresponding author at n.ismail@keele.ac.uk.
What is already known on this topic

- Oral antithrombotics are effective in reducing ischaemic events albeit at the expense of increased risk of bleeding.

- These bleeding complications continue to occur even after hospital discharge post-ACS.

- The rate and prognostic impact of bleeding events that occur in the in-hospital settings has been well established whereas the rate of bleeds that occur in the longer term after hospital discharge and their prognostic impacts are unclear.

What this study adds

- Bleeds post hospital discharge for ACS are common, especially within the first 3 months.

- These bleeds vary by severity, anatomic source and discharge antithrombotic therapy.

- These longer term bleeding complications may increase the risk of mortality, MACE and rehospitalisation.
REFERENCES

1. O’Connor RE, Brady W, Brooks SC, et al. Part 10: Acute Coronary Syndromes. *Circulation*. 2010;122(18 suppl 3).

2. Cayla G, Cuisset T, Silvain J, et al. Prasugrel Monitoring and Bleeding in Real World Patients. *Am J Cardiol*. 2013;111(1):38-44. doi:10.1016/j.amjcard.2012.08.043.

3. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. *J Am Coll Cardiol*. 2015;65(20):2211-2221. doi:10.1016/j.jacc.2015.03.003.

4. Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. *Eur Heart J*. 2008;30(8):900-907. doi:10.1093/eurheartj/ehn417.

5. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. *J Am Coll Cardiol*. 2007;50(18):1742-1751. doi:10.1016/j.jacc.2007.07.042.

6. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. *J Am Coll Cardiol*. 2009;53(22):2019-2027. doi:10.1016/j.jacc.2008.12.073.

7. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? *Circulation*. 2007. doi:10.1161/CIRCULATIONAHA.107.694273.

8. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. *Am J Cardiol*. 2003;92(8):930-935. doi:10.1016/S0002-9149(03)00972-X.

9. Kwok CS, Rao S V, Myint PK, et al. Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. *Open Hear*. 2014;1(1):e00021. doi:10.1136/openhrt-2013-00021.

10. Kwok CS, Khan MA, Rao S V., et al. Access and Non–Access Site Bleeding After Percutaneous Coronary Intervention and Risk of Subsequent Mortality and Major Adverse Cardiovascular Events. *Circ Cardiovasc Interv*. 2015;8(4).
16. Wells GA, Shea B, O’Connell D, Peterson J, welch V, Losos M TP. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. 2011.

17. Zhu W, Wan R, Liu F, et al. Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review. *J Am Heart Assoc.* 2016;5(9).

18. SIGN (Scottish Intercollegiate Guideline Network). Critical appraisal: Notes and checklists.

19. Owens DK, Lohr KN, Atkins D, et al. AHRQ Series Paper 5: Grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol.* 2010;63(5):513-523. doi:10.1016/j.jclinepi.2009.03.009.

20. Amin AP, Bachuwar A, Reid KJ, et al. Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status. *J Am Coll Cardiol.* 2013;61(21):2130-2138. doi:10.1016/j.jacc.2013.02.044.

21. Amin AP, Wang TY, McCoy L, et al. Impact of Bleeding on Quality of Life in Patients on DAPT: Insights From TRANSITIZE-ACS. *J Am Coll Cardiol.* 2016;67(1):59-65. doi:10.1016/j.jacc.2015.10.034.

22. Bacquelin R, Oger E, Filippi E, et al. Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). *Arch Cardiovasc Dis.* 2016;109(1):31-38. doi:10.1016/j.acvd.2015.08.005.

23. Barra S, Providência R, Caetano F, et al. BLEED-Myocardial Infarction Score: Predicting mid-term post-discharge bleeding events. *World J Cardiol.* 2013;5(6):196-206. doi:10.4330/wjc.v5.i6.196.

24. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. *Lancet (London, England).* 1994;343(8896):499-503.

25. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP-GPRD). *Eur Heart J.* 2011;32(19):2376-2386. doi:10.1093/eurheartj/ehr340.

26. Braun OÖ, Bico B, Chaudhry U, et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. *Thromb Res.* 2015;135(1):26-30. doi:10.1016/j.thromres.2014.10.016.

27. Chamberlain AM, Gersh BJ, Mills RM, et al. Antithrombotic strategies and outcomes in acute coronary syndrome with atrial fibrillation. *Am J Cardiol.* 2015;115(8):1042-1048. doi:10.1016/j.amjcard.2015.01.534.

28. Carrero J-J, Varenhorst C, Jensevik K, et al. Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. *Kidney Int.* 2017;91(1):216-226. doi:10.1016/j.kint.2016.09.014.

29. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? *EuroIntervention.* 2009;5(3):325-329.

30. Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non–ST elevation myocardial infarction. *Am Heart J.* 2012;163(4):720-728. doi:10.1016/j.ahj.2012.01.017.
31. Graipe A, Binsell-Gerdin E, S€ Oderstr€ Om L, Mooe T. Incidence, Time Trends, and Predictors of Intracranial Hemorrhage During Long-Term Follow-up After Acute Myocardial Infarction. doi:10.1161/JAHA.115.002290.
32. Han Y, Guo J, Zheng Y, et al. Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. *JAMA*. 2015;313(13):1336. doi:10.1001/jama.2015.2323.
33. Kassaian SE, Masoudkabir F, Sezavar H, et al. Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2). *BMJ Open*. 2015;5(12):e007786. doi:10.1136/bmjopen-2015-007786.
34. Khan R, Lopes RD, Neely ML, et al. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. *Heart*. 2015;101(18):1475-1484. doi:10.1136/heartjnl-2014-307346.
35. Kohli P, Udell JA, Murphy SA, et al. Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel. *J Am Coll Cardiol*. 2014;63(3):225-232. doi:10.1016/j.jacc.2013.09.023.
36. Lattuca B, Fabbro-Peray P, Leclercq F, et al. One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. *Arch Cardiovasc Dis*. 2016;109(5):337-347. doi:10.1016/j.acvd.2016.01.009.
37. Mahaffey KW, Huang Z, Wallentin L, et al. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). *Am J Cardiol*. 2014;113(6):936-944. doi:10.1016/j.amjcard.2013.11.052.
38. Mrdovic I, Savic L, Asanin M, et al. Sex-Related Analysis of Short- and Long-term Clinical Outcomes and Bleeding Among Patients Treated With Primary Percutaneous Coronary Intervention: An Evaluation of the RISK-PCI Data. *Can J Cardiol*. 2013;29(9):1097-1103. doi:10.1016/j.cjca.2012.11.013.
39. Schjerning Olsen A-M, Gislason GH, McGettigan P, et al. Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction. *JAMA*. 2015;313(8):805. doi:10.1001/jama.2015.0809.
40. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. *Lancet (London, England)*. 2009;374(9706):1967-1974. doi:10.1016/S0140-6736(09)61751-7.
41. Sra S, Tan MK, Mehta SR, et al. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. *Am Heart J*. 2016;180:82-89. doi:10.1016/j.ahj.2016.07.015.
42. Savonitto S, Cavallini C, Petronio AS, et al. Early Aggressive Versus Initially Conservative Treatment in Elderly Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. *JACC Cardiovasc Interv*. 2012;5(9):906-916. doi:10.1016/j.jcin.2012.06.008.
43. Voss B, Lee M, Devlin GP, Kerr AJ. Incidence and type of bleeding complications early and late after acute coronary syndrome admission in a New Zealand cohort (ANZACS-QI-7). *N Z Med J*. 2016;129(1437):27-38.
44. Wang Y, Lichtman JH, Dharmarajan K, et al. National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010. *Am
45. Wong P, Robinson A, Shaw S, Rodrigues E. Long term clinical outcome and bleeding complications among hospital survivors with acute coronary syndromes. *Postgrad Med J*. 2006;82(965):224-227. doi:10.1136/pgmj.2005.040097.

46. Blin P, Dureau-Pournin C, Lassalle R, et al. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database. *Br J Clin Pharmacol*. 2017;83(9):2056-2065. doi:10.1111/bcp.13291.

47. Brinkert M, Southern DA, James MT, Knudtson ML, Anderson TJ, Charbonneau F. Incidence and Prognostic Implications of Late Bleeding After Myocardial Infarction or Unstable Angina According to Treatment Strategy. *Can J Cardiol*. 2017;33(8):998-1005. doi:10.1016/j.cjca.2017.05.001.

48. Caneiro-Queija B, Abu-Assi E, Raposeiras-Roubin S, et al. Differential Prognostic Impact on Mortality of Myocardial Infarction Compared With Bleeding Severity in Contemporary Acute Coronary Syndrome Patients. *Rev Española Cardiol (English Ed).* April 2018. doi:10.1016/j.rec.2018.02.008.

49. Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. *Eur Heart J*. 2017;38(41):3070-3078. doi:10.1093/eurheartj/ehx175.

50. Effron MB, Nair K V., Molife C, et al. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database. *Am J Cardiovasc Drugs*. 2018;18(2):129-141. doi:10.1007/s40256-017-0255-y.

51. Ertaş FS, Tokgozoglu L, EPICOR Study Group. Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients. *Turk Kardiyol Dern Ars*. 2018;46(3):175-183. doi:10.5543/TKDA.2017.66724.

52. Raposeiras-Roubín S, Caneiro Queija B, D'Ascenzo F, et al. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome. *Rev Española Cardiol (English Ed).* July 2018. doi:10.1016/j.rec.2018.06.004.

53. Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. *Eur Heart J*. 2016;38(11):ehw525. doi:10.1093/eurheartj/ehw525.

54. Yetgin T, Boersma E, Smits PC, et al. One-year efficacy and safety of routine prasugrel in patients with acute coronary syndromes treated with percutaneous coronary intervention: results of the prospective rijnmont collective cardiology research study. *Netherlands Hear J*. 2018;26(7-8):393-400. doi:10.1007/s12471-018-1126-0.

55. Garay A, Ariza-Solé A, Formiga F, et al. Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry. *Thromb Haemost*. 2018;118(5):929-938. doi:10.1055/s-0038-1635259.

56. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. *N Engl J Med*. 2006;354(14):1464-1476. doi:10.1056/NEJMoa055443.

57. Brener SJ, Kirtane AJ, Stuckey TD, et al. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2016;9(14).
58. Nikolsky E, Mehran R, Dangas GD, et al. Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segment-Elevation Myocardial Infarction: Analysis From the HORIZONS-AMI Trial. *Circ Cardiovasc Interv.* 2015;8(4):e002283-e002283. doi:10.1161/CIRCINTERVENTIONS.114.002283.

59. Palmerini T, Calabrò P, Piscione F, et al. Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2014;7(10):1117-1127. doi:10.1016/j.jcin.2014.02.013.

60. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the Orbofibin in Patients with Unstable coronary Syndromes–Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. *Am Heart J.* 2006;151(5):976.e1-976.e6. doi:10.1016/j.ahj.2006.02.013.

61. Cuschieri JR, Drawz P, Falck-Ytter Y, Wong RCK. Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. *J Dig Dis.* 2014;15(4):195-201. doi:10.1111/1751-2980.12123.

62. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding Complications Associated With Combinations of Aspirin, Thienopyridine Derivatives, and Warfarin in Elderly Patients Following Acute Myocardial Infarction. *Arch Intern Med.* 2005;165(7):784. doi:10.1001/archinte.165.7.784.

63. Carrabba N, Parodi G, Marcucci R, et al. Bleeding events and maintenance dose of prasugrel: BLESS pilot study. *Open Hear.* 2016;3(2):e000460. doi:10.1136/openhrt-2016-000460.

64. Lamberts M, Gislason GH, Olesen JB, et al. Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. *J Am Coll Cardiol.* 2013;62(11):981-989. doi:10.1016/j.jacc.2013.05.029.

65. Tsai Y-W, Wen Y-W, Huang W-F, Chen P-F, Kuo KN, Hsiao F-Y. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. *J Gastroenterol.* 2011;46(1):39-45. doi:10.1007/s00535-010-0299-0.

66. Costa F, Vranckx P, Leonardi S, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. *Eur Heart J.* 2015;36(20):1242-1251. doi:10.1093/eurheartj/ehv038.

67. Bonaca MP, Bhatt DL, Cohen M, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. *N Engl J Med.* 2015;372(19):1791-1800. doi:10.1056/NEJMoa1500857.

68. Ko DT, Yun L, Wijeyesundera HC, et al. Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years. *Circ Cardiovasc Interv.* 2010;3(2):140-147. doi:10.1161/CIRCINTERVENTIONS.109.928721.

69. Kazi DS, Leong TK, Chang TI, Solomon MD, Hlatky MA, Go AS. Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. *J Am Coll Cardiol.* 2015;65(14):1411-1420. doi:10.1016/j.jacc.2015.01.047.
Garay A, Ariza-Solé A, Abu-Assi E, Lorente V, Sánchez-Salado JC, Cequier Á. Mid Term Bleeding Risk Prediction After an Acute Coronary Syndrome: An Unsolved Question. Rev Española Cardiol (English Ed). 2016;69(5):527-529. doi:10.1016/j.rec.2016.02.003.

Tsai Y-W, Wen Y-W, Huang W-F, Chen P-F, Kuo KN, Hsiao F-Y. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol. 2011;46(1):39-45. doi:10.1007/s00535-010-0299-0.

Hamm CW, Bassand J-P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Jeroen J Bax. 2011. doi:10.1093/eurheartj/ehr236.

Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-2619. doi:10.1093/eurheartj/ehs215.

Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Circulation. 2014;130(25).

Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735. doi:10.1001/jama.2016.3775.

Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-1034. doi:10.1016/S0140-6736(17)30397-5.

Raposeiras-Roubín S, Faxén J, Íñiguez-Romo A, et al. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score. Int J Cardiol. 2018;254:10-15. doi:10.1016/j.ijcard.2017.10.103.

Alfredsson J, Neely B, Neely ML, et al. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart. 2017;103(15):1168-1176. doi:10.1136/heartjnl-2016-310090.

Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. Am J Cardiol. 2005;95(10):1218-1222. doi:10.1016/j.amjcard.2005.01.049.

García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. Eckle T, ed. PLoS One. 2016;11(8):e0160046. doi:10.1371/journal.pone.0160046.

Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. August 2017. doi:10.1093/eurheartj/ehx393.

Mehran R, Pocock SJ, Nikolsky E, et al. A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2010;55(23).

Subherwal S, Bach RG, Chen AY, et al. Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction. Circulation. 2009;119(14).

Mathews R, Peterson ED, Chen AY, et al. In-Hospital Major Bleeding During ST-
Elevation and Non–ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG\textsuperscript{TM}. *Am J Cardiol.* 2011;107(8):1136-1143. doi:10.1016/j.amjcard.2010.12.009.

85. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry. *Circ Cardiovasc Interv.* 2009;2(3):222-229. doi:10.1161/CIRCINTERVENTIONS.108.846741.
**Figure 1:** Prisma flow chart depicting steps involved in selecting or rejecting studies for inclusion in the review.
Figure 2: Cumulative incidence of bleeding as reported within individual studies at different time points (incidence expressed as proportion per 100 persons)